Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
Healthcare
$2.09 +2.96%
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
52W Low $1.58High $9.22
Volume 0.03M
Average 0.16M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$19.21M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$23.72M
FY 2025 · Annual
-13.8% YoYCash Flow Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (20.16M) | (24.74M) | (27.29M) | (22.23M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 654.07K | 423.54K | 2M | 6.05M |
| Change in Working Capital | 1.73M | 2.57M | 1.1M | (3.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 586.26K | 1.29M | (1.5M) | (512.54K) |
| Other Working Capital | 1.15M | 1.28M | 2.6M | (2.53M) |
| Other Non-Cash Items | (20.38K) | 123.46K | 2.35M | 20.25K |
| Operating Cash Flow | (17.79M) | (21.63M) | (21.84M) | (19.21M) |
| Capital Expenditures | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 5.5M | 0 |
| Common Stock Issued | 0 | 0 | 23.96M | 24.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (1.93M) | (302.83K) |
| Financing Cash Flow | 19.26M | 4.13M | 27.53M | 23.72M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.46M | (17.49M) | 5.68M | 4.52M |
| Free Cash Flow | (17.79M) | (21.63M) | (21.84M) | (19.21M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$22.2M
+ D&A$0
+ Stock-Based Comp$6.0M
+ Deferred Tax$0
- Working Capital-$3.0M
+ Other Non-Cash$20.3K
= Operating Cash Flow-$19.2M
- Capex$0
= Free Cash Flow-$19.2M
Analysis
FY2025 free cash flow is -$19.2M. FCF conversion is 86.4% of net income. Operating cash flow was -$19.2M, with capex of $0. The largest bridge item is Stock-Based Comp at $6.0M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | May 22, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 22, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 22, 2026 | |
| 8-K | Current report | May 22, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 22, 2026 |
Does ACTU generate free cash flow?
Actuate Therapeutics Inc (ACTU) generated -$19.21M of free cash flow in fiscal 2025.
How much operating cash flow does ACTU produce?
Operating cash flow was -$19.21M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.